Loading
NASDAQHealthcareMedical - Healthcare Information Services
Latest quote
$70.40
+$1.12 · +1.62%
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Regular session
$70.0364
+$0.7564 · +1.09%
Regular session · ET · Market data may be delayed.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Day range
Current $70.0364
52-week range
Current $70.0364
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
47
Mixed
Risk
82
Extreme Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Day range
Current $70.0364
52-week range
Current $70.0364
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.27B USD | 693.4M USD | 531.82M USD | 320.67M USD | 257.85M USD |
| Cost of goods sold | 473.89M USD | 312.29M USD | 245.65M USD | 190.48M USD | 174.21M USD |
| Gross profit | 797.9M USD | 381.11M USD | 286.18M USD | 130.19M USD | 83.64M USD |
| Research and development | 319.03M USD | 316.84M USD | 185.5M USD | 162.25M USD | 128.35M USD |
| Selling, general, and administrative | 715.43M USD | 755.35M USD | 296.76M USD | 233.38M USD | 199M USD |
| Operating expenses | 1.05B USD | 1.07B USD | 482.26M USD | 395.63M USD | 327.36M USD |
| Interest income | 12.63M USD | 11.08M USD | 7.6M USD | 3.03M USD | 623K USD |
| Interest expense | 70.27M USD | 53.65M USD | 46.87M USD | 21.89M USD | 15.18M USD |
| Depreciation and amortization | 102.32M USD | 37.25M USD | 33.33M USD | 30.41M USD | 23.88M USD |
| Operating income | −252.87M USD | −691.08M USD | −196.08M USD | −265.44M USD | −243.71M USD |
| Net income | −245.03M USD | −705.81M USD | −214.12M USD | −289.81M USD | −259.19M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK343.99M5.00%5.56B USD0.75%$89.63+2.32%
Vanguard Morningstar Total Stock Market ETFVTI227.53M0.01%2.3T USD0.03%$381.59+0.53%
ARK Genomic Revolution ETFARKG170.21M8.30%1.56B USD0.75%$51.40+4.28%
Vanguard Morningstar Small-Cap ETFVB164.58M0.09%185.3B USD0.03%$288.79+0.40%
Vanguard Morningstar Small-Cap Growth ETFVBK94.47M0.21%44.7B USD0.05%$343.18+0.76%
Vanguard Extended Market ETFVXF75.5M0.08%95.4B USD0.05%$234.38+0.53%
iShares Biotechnology ETFIBB57.81M0.55%10.41B USD0.44%$205.63+2.57%
JPMorgan U.S. Tech Leaders ETFJTEK56.01M1.15%4.8B USD0.65%$107.35+1.27%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBJPMorgan U.S. Tech Leaders ETFJTEKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
